Literature DB >> 26838312

Novel Insights Into the Mechanisms Regulating Pro-Atrial Natriuretic Peptide Cleavage in the Heart and Blood Pressure Regulation: Proprotein Convertase Subtilisin/Kexin 6 Is the Corin Activating Enzyme.

Massimo Volpe1, Speranza Rubattu1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26838312     DOI: 10.1161/CIRCRESAHA.115.307875

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  6 in total

Review 1.  The Natriuretic Peptides for Hypertension Treatment.

Authors:  Speranza Rubattu; Giovanna Gallo
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-11-02

Review 2.  Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk.

Authors:  Riccardo Sarzani; Francesco Spannella; Federico Giulietti; Paolo Balietti; Guido Cocci; Marica Bordicchia
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-04

Review 3.  The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases.

Authors:  Speranza Rubattu; Sebastiano Sciarretta; Simona Marchitti; Franca Bianchi; Maurizio Forte; Massimo Volpe
Journal:  Int J Mol Sci       Date:  2018-02-11       Impact factor: 5.923

Review 4.  Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review.

Authors:  Shihui Fu; Ping Ping; Qiwei Zhu; Ping Ye; Leiming Luo
Journal:  Front Physiol       Date:  2018-06-05       Impact factor: 4.566

Review 5.  Mouse Models of Human Proprotein Convertase Insufficiency.

Authors:  Manita Shakya; Iris Lindberg
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

6.  Serum PCSK6 and corin levels are not associated with cardiovascular outcomes in patients undergoing coronary angiography.

Authors:  Shang-Feng Yang; Ruey-Hsing Chou; Shing-Jong Lin; Szu-Yuan Li; Po-Hsun Huang
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.